News Amjevita, first Humira biosimilar approved – but no launch y... Amgen's biosimilar is ready to go, but AbbVie believes it can delay until 2022
News Biosimilar junket: Hospira took UK pharmacists to 5-star hot... Hospira trip ruled to be disguised promotion
News Bad news for Sanofi as biosimilar replaces Lantus Pharmacy benefit firm axes Lantus, decision due on key combination therapy.
News Biosimilar switching not suitable for all patients Antibodies against originator will also target biosimilar.
News Biogen eyeing big-selling biosimilars as MS drug fails Gamble on opicinumab looks unlikely to pay off.
Articles Healthcare systems aren’t making the most of biosimilars: ph... Biosimilars could save European and US healthcare systems billions - but more needs to be done to maximise their benefits, writes Richard Staines.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
